	US 12,133,920 B2
	Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
Martin Purpura, Austin, TX (US); Ralf Jäger, Milwaukee, WI (US); Jie Gu, Shanghai (CN); Xiong Zheng, Shanghai (CN); Lingwei Dai, Shanghai (CN); and Yaohua Zhang, Shangahi (CN)
Assigned to TSI Group Co. Ltd., (CN)
Filed by TSI Group Ltd., Missoula, MT (US)
Filed on Mar. 30, 2021, as Appl. No. 17/217,913.
Application 17/217,913 is a continuation of application No. 15/605,664, filed on May 25, 2017, granted, now 10,959,957, issued on Mar. 30, 2021.
Claims priority of provisional application 62/341,464, filed on May 25, 2016.
Prior Publication US 2021/0212953 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/48 (2006.01); A61K 31/19 (2006.01)

CPC A61K 9/4816 (2013.01) [A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/19 (2013.01)]

9 Claims

1. A soft gel capsule comprising:

a. a capsule shell; and

b. a liquid formulation comprising 3-hydroxy-3-methylbutyric acid and at least one excipient,

wherein the soft gel capsule is shelf-stable,

wherein the at least one excipient is betaine,

wherein the at least one excipient lessens the hygroscopicity of the soft gel capsule.